Literature DB >> 10881018

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

G N Thalmann1, R A Sikes, T T Wu, A Degeorges, S M Chang, M Ozen, S Pathak, L W Chung.   

Abstract

BACKGROUND: Clinically, the lethal phenotypes of human prostate cancer are characterized by their progression to androgen-independence and their propensity to form osseous metastases. We reported previously on the establishment of androgen-independent (AI) human prostate cancer cell lines derived from androgen-dependent (AD) LNCaP cells, with androgen independence defined as the capability of prostate cancer cells to grow in castrated hosts. One of the sublines, C4-2, was found to be AI, highly tumorigenic, and metastatic, having a proclivity for metastasis to the bone.
METHODS: We established the AI and bone metastatic cell sublines B2, B3, B4, and B5 from the parental C4-2 subline, using a previously established coinoculating procedure. We determined the biologic behavior of the parental and derivative LNCaP sublines in vivo and in vitro, as well as their molecular and cytogenetic characteristics.
RESULTS: Unlike other human prostate cancer models, the LNCaP progression model shares remarkable similarities with human prostate cancer. We observed a comparable pattern of metastasis from the primary to the lymph node and to the axial skeleton, with a predominant phenotype of osteoblastic reaction; 25-37.5% of the animals developed paraplegia. Cytogenetic and biochemical characterizations of LNCaP sublines also indicate close similarities between human prostate cancer and the LNCaP progression model. Additional chromosomal changes were detected in B2-B5 sublines derived from C4-2 bone metastases. These LNCaP sublines were found to grow faster under anchorage-dependent but not -independent conditions. The in vitro invasion and in vivo metastatic potential of these LNCaP sublines surprisingly correlated with anchorage-dependent and not -independent growth. The derivative LNCaP sublines when cultured in vitro produced a substantially higher (20-30-fold) amount of basal steady-state concentrations of PSA than that of the parental LNCaP cells. PSA production was high initially, but was markedly reduced when the derivative cell lines were inoculated and allowed to grow long-term in vivo for the establishment of tumors and metastasis, suggesting that unknown host factors derived either from the prostate or the bone can effectively downregulate PSA expression by prostate tumor epithelium.
CONCLUSIONS: The LNCaP model of human prostate cancer progression will help improve our understanding of the mechanisms of androgen-independence and osseous metastasis, and tumor-host determinants of PSA expression. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881018     DOI: 10.1002/1097-0045(20000701)44:2<91::aid-pros1>3.0.co;2-l

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  134 in total

1.  Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells.

Authors:  David J Degraff; Adam A Aguiar; Qian Chen; Lisa K Adams; B Jill Williams; Robert A Sikes
Journal:  Am J Transl Res       Date:  2010-03-06       Impact factor: 4.060

2.  Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Authors:  Mandeep S Virk; Farhang Alaee; Frank A Petrigliano; Osamu Sugiyama; Arion F Chatziioannou; David Stout; William C Dougall; Jay R Lieberman
Journal:  Bone       Date:  2010-11-10       Impact factor: 4.398

3.  Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.

Authors:  Wen-Chin Huang; Xiangyan Li; Jian Liu; Jentai Lin; Leland W K Chung
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

Review 4.  Regulation of mitochondrial DNA content and cancer.

Authors:  Masahiro Higuchi
Journal:  Mitochondrion       Date:  2006-12-05       Impact factor: 4.160

5.  The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.

Authors:  Anthony J Saporita; Junkui Ai; Zhou Wang
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

6.  Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Authors:  Jami Mandelin; Marina Cardó-Vila; Wouter H P Driessen; Paul Mathew; Nora M Navone; Sue-Hwa Lin; Christopher J Logothetis; Anna Cecilia Rietz; Andrey S Dobroff; Bettina Proneth; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-11       Impact factor: 11.205

Review 7.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

8.  Radiation modulation of microRNA in prostate cancer cell lines.

Authors:  Sajni Josson; Shian-Ying Sung; Kaiqin Lao; Leland W K Chung; Peter A S Johnstone
Journal:  Prostate       Date:  2008-11-01       Impact factor: 4.104

9.  Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells.

Authors:  Katayoon H Emami; Lisha G Brown; Tiffany E M Pitts; Xizhang Sun; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

10.  Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Authors:  Mark A Castanares; Ben T Copeland; Wasim H Chowdhury; Minzhi M Liu; Ronald Rodriguez; Martin G Pomper; Shawn E Lupold; Catherine A Foss
Journal:  Prostate       Date:  2015-10-26       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.